JP2013518845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518845A5 JP2013518845A5 JP2012551586A JP2012551586A JP2013518845A5 JP 2013518845 A5 JP2013518845 A5 JP 2013518845A5 JP 2012551586 A JP2012551586 A JP 2012551586A JP 2012551586 A JP2012551586 A JP 2012551586A JP 2013518845 A5 JP2013518845 A5 JP 2013518845A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- methyl
- trans
- cyclohexyl
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 150000003839 salts Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims 5
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims 5
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- -1 4-((4- (4-chlorophenyl) -5-methyl-1H-pyrazol-3-ylamino) methyl) cyclohexyl Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- GSQGCFTWOSTTHY-UHFFFAOYSA-N 5-chloro-2-methyl-n-[4-[(3,4,5-trimethylpyrazol-1-yl)methyl]cyclohexyl]pyridine-3-carboxamide Chemical compound CC1=C(C)C(C)=NN1CC1CCC(NC(=O)C=2C(=NC=C(Cl)C=2)C)CC1 GSQGCFTWOSTTHY-UHFFFAOYSA-N 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- CWCYNBYBTACELK-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)-n-[4-[(3,4,5-trimethylpyrazol-1-yl)methyl]cyclohexyl]benzamide Chemical compound CC1=C(C)C(C)=NN1CC1CCC(NC(=O)C=2C(=CC=C(C=2)C(F)(F)F)Cl)CC1 CWCYNBYBTACELK-UHFFFAOYSA-N 0.000 claims 1
- AIAQEHWTQAOGLA-UHFFFAOYSA-N 2-chloro-n-[4-[(3-phenylpyrazol-1-yl)methyl]cyclohexyl]-5-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=C(Cl)C(C(=O)NC2CCC(CN3N=C(C=C3)C=3C=CC=CC=3)CC2)=C1 AIAQEHWTQAOGLA-UHFFFAOYSA-N 0.000 claims 1
- QJLODLOESBNNPM-UHFFFAOYSA-N 2-chloro-n-[4-[(4-chloro-3,5-dimethylpyrazol-1-yl)methyl]cyclohexyl]-5-(trifluoromethyl)benzamide Chemical compound CC1=C(Cl)C(C)=NN1CC1CCC(NC(=O)C=2C(=CC=C(C=2)C(F)(F)F)Cl)CC1 QJLODLOESBNNPM-UHFFFAOYSA-N 0.000 claims 1
- SUUSNFSQMHCMDE-UHFFFAOYSA-N 2-chloro-n-[4-[[3-(4-methoxyphenyl)-5-methylpyrazol-1-yl]methyl]cyclohexyl]-5-(trifluoromethyl)benzamide Chemical compound C1=CC(OC)=CC=C1C1=NN(CC2CCC(CC2)NC(=O)C=2C(=CC=C(C=2)C(F)(F)F)Cl)C(C)=C1 SUUSNFSQMHCMDE-UHFFFAOYSA-N 0.000 claims 1
- MRZCTSJNLTVOQB-UHFFFAOYSA-N 2-chloro-n-[4-[[4-chloro-3-(hydroxymethyl)pyrazol-1-yl]methyl]cyclohexyl]-5-(trifluoromethyl)benzamide Chemical compound C1=C(Cl)C(CO)=NN1CC1CCC(NC(=O)C=2C(=CC=C(C=2)C(F)(F)F)Cl)CC1 MRZCTSJNLTVOQB-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- YFGJKTCILASHFF-UHFFFAOYSA-N 5-chloro-n-[4-[(3,5-diethylpyrazol-1-yl)methyl]cyclohexyl]-2-methylpyridine-3-carboxamide Chemical compound N1=C(CC)C=C(CC)N1CC1CCC(NC(=O)C=2C(=NC=C(Cl)C=2)C)CC1 YFGJKTCILASHFF-UHFFFAOYSA-N 0.000 claims 1
- FZPRQRQELHONGW-UHFFFAOYSA-N 5-chloro-n-[4-[(3,5-dimethylpyrazol-1-yl)methyl]cyclohexyl]-2-methylpyridine-3-carboxamide Chemical compound N1=C(C)C=C(C)N1CC1CCC(NC(=O)C=2C(=NC=C(Cl)C=2)C)CC1 FZPRQRQELHONGW-UHFFFAOYSA-N 0.000 claims 1
- JRBVOUREXIRPPY-UHFFFAOYSA-N 5-chloro-n-[4-[(4-chloro-3,5-dimethylpyrazol-1-yl)methyl]cyclohexyl]-2-methylpyridine-3-carboxamide Chemical compound CC1=C(Cl)C(C)=NN1CC1CCC(NC(=O)C=2C(=NC=C(Cl)C=2)C)CC1 JRBVOUREXIRPPY-UHFFFAOYSA-N 0.000 claims 1
- KQQMWFWXNSJHJA-UHFFFAOYSA-N 5-chloro-n-[4-[[(5-ethyl-4-methyl-1h-pyrazol-3-yl)amino]methyl]cyclohexyl]-2-methylpyridine-3-carboxamide Chemical compound CC1=C(CC)NN=C1NCC1CCC(NC(=O)C=2C(=NC=C(Cl)C=2)C)CC1 KQQMWFWXNSJHJA-UHFFFAOYSA-N 0.000 claims 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 1
- CVWWTNXFLUGTDI-ZHTAKFGLSA-N CC(C(O)=O)c1ccc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1 Chemical compound CC(C(O)=O)c1ccc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1 CVWWTNXFLUGTDI-ZHTAKFGLSA-N 0.000 claims 1
- DLODGACIEXJIID-KOMQPUFPSA-N CC(C)(C)c1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound CC(C)(C)c1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 DLODGACIEXJIID-KOMQPUFPSA-N 0.000 claims 1
- WQYAOEVXNPHQHJ-JCNLHEQBSA-N CC(C)c1c(C)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound CC(C)c1c(C)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F WQYAOEVXNPHQHJ-JCNLHEQBSA-N 0.000 claims 1
- CSYALHPPMSVBIL-SAABIXHNSA-N CC(C)c1cc(C(C)C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound CC(C)c1cc(C(C)C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 CSYALHPPMSVBIL-SAABIXHNSA-N 0.000 claims 1
- XIRJFRYFIXCOCZ-SAABIXHNSA-N CC(C)c1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 Chemical compound CC(C)c1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 XIRJFRYFIXCOCZ-SAABIXHNSA-N 0.000 claims 1
- VFTPTHOIZIMBGU-SAABIXHNSA-N CC(C)c1cc(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C Chemical compound CC(C)c1cc(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C VFTPTHOIZIMBGU-SAABIXHNSA-N 0.000 claims 1
- FKFUKPZBLDIDCA-KOMQPUFPSA-N CC(C)c1cc(CO)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound CC(C)c1cc(CO)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F FKFUKPZBLDIDCA-KOMQPUFPSA-N 0.000 claims 1
- KTYIVOVFFAQTSQ-SAABIXHNSA-N CC(C)c1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)cc1C Chemical compound CC(C)c1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)cc1C KTYIVOVFFAQTSQ-SAABIXHNSA-N 0.000 claims 1
- VDHCHJQTFOXAKF-JCNLHEQBSA-N CC(C)c1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1C Chemical compound CC(C)c1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1C VDHCHJQTFOXAKF-JCNLHEQBSA-N 0.000 claims 1
- SIVDZRMKCXLRPY-CZIWCDLHSA-N CC1=NC=C(Cl)C=C1C(=O)N[C@@H]1CC[C@@H](CN2C=3CCCC=3C=N2)CC1 Chemical compound CC1=NC=C(Cl)C=C1C(=O)N[C@@H]1CC[C@@H](CN2C=3CCCC=3C=N2)CC1 SIVDZRMKCXLRPY-CZIWCDLHSA-N 0.000 claims 1
- UVKGWNIRLPNREG-CZIWCDLHSA-N CC1=NC=C(Cl)C=C1C(=O)N[C@@H]1CC[C@@H](CN2N=C3CCCC3=C2)CC1 Chemical compound CC1=NC=C(Cl)C=C1C(=O)N[C@@H]1CC[C@@H](CN2N=C3CCCC3=C2)CC1 UVKGWNIRLPNREG-CZIWCDLHSA-N 0.000 claims 1
- VCERYFYYVGYTNI-KOMQPUFPSA-N CCOC(=O)c1c(C)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound CCOC(=O)c1c(C)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F VCERYFYYVGYTNI-KOMQPUFPSA-N 0.000 claims 1
- PZRFQJADLUWQGZ-MQMHXKEQSA-N CCOC(=O)c1c(Cl)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound CCOC(=O)c1c(Cl)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F PZRFQJADLUWQGZ-MQMHXKEQSA-N 0.000 claims 1
- WLLGCGVEZFNTLJ-CTYIDZIISA-N CCOC(=O)c1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound CCOC(=O)c1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 WLLGCGVEZFNTLJ-CTYIDZIISA-N 0.000 claims 1
- BRXWMNWQXMTVID-CTYIDZIISA-N CCOC(=O)c1ccnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound CCOC(=O)c1ccnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F BRXWMNWQXMTVID-CTYIDZIISA-N 0.000 claims 1
- XZMXFOVTHOXSOH-KOMQPUFPSA-N CCOC(=O)c1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1C Chemical compound CCOC(=O)c1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1C XZMXFOVTHOXSOH-KOMQPUFPSA-N 0.000 claims 1
- VBHAOZNATJEEMB-JCNLHEQBSA-N CCc1c(C)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C Chemical compound CCc1c(C)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C VBHAOZNATJEEMB-JCNLHEQBSA-N 0.000 claims 1
- LMFKNZJLPGRGKR-KOMQPUFPSA-N CCc1c(C)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound CCc1c(C)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F LMFKNZJLPGRGKR-KOMQPUFPSA-N 0.000 claims 1
- FSQVOSCRZKKFOF-CTYIDZIISA-N CCc1c(Cl)c(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound CCc1c(Cl)c(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F FSQVOSCRZKKFOF-CTYIDZIISA-N 0.000 claims 1
- KUKANTJOKSAEMK-CZIWCDLHSA-N CCc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound CCc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 KUKANTJOKSAEMK-CZIWCDLHSA-N 0.000 claims 1
- CQDAKWJVFKETDG-KOMQPUFPSA-N CCc1cc(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound CCc1cc(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F CQDAKWJVFKETDG-KOMQPUFPSA-N 0.000 claims 1
- YRZWOGUFXLWUKM-CZIWCDLHSA-N CCc1cc(CC)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound CCc1cc(CC)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 YRZWOGUFXLWUKM-CZIWCDLHSA-N 0.000 claims 1
- VNUJFEHKOZBNKG-JCNLHEQBSA-N CCc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)cc1C Chemical compound CCc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)cc1C VNUJFEHKOZBNKG-JCNLHEQBSA-N 0.000 claims 1
- WYPKJBZTZFZUPF-CTYIDZIISA-N CCc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c(C)c1Cl Chemical compound CCc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c(C)c1Cl WYPKJBZTZFZUPF-CTYIDZIISA-N 0.000 claims 1
- KUHXDWVHYWXSOZ-CTYIDZIISA-N CCc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c(CC)c1Cl Chemical compound CCc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c(CC)c1Cl KUHXDWVHYWXSOZ-CTYIDZIISA-N 0.000 claims 1
- UXTJTLDUDAQOMQ-KOMQPUFPSA-N CCc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1C Chemical compound CCc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1C UXTJTLDUDAQOMQ-KOMQPUFPSA-N 0.000 claims 1
- UFNOQJNGEZPSNX-MQMHXKEQSA-N COc1c(Cl)c(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound COc1c(Cl)c(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F UFNOQJNGEZPSNX-MQMHXKEQSA-N 0.000 claims 1
- LUOQQPVHUYVFNA-KOMQPUFPSA-N COc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 Chemical compound COc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 LUOQQPVHUYVFNA-KOMQPUFPSA-N 0.000 claims 1
- ASLHIRDCUBBIEL-CTYIDZIISA-N COc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound COc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 ASLHIRDCUBBIEL-CTYIDZIISA-N 0.000 claims 1
- JOSMVOMZCLJNAS-KOMQPUFPSA-N COc1cc(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C Chemical compound COc1cc(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C JOSMVOMZCLJNAS-KOMQPUFPSA-N 0.000 claims 1
- KJEKFLMCRQCNRL-CTYIDZIISA-N COc1cc(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound COc1cc(C)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F KJEKFLMCRQCNRL-CTYIDZIISA-N 0.000 claims 1
- WYTQVDBYGFCFCU-CTYIDZIISA-N COc1ccc(Cl)c(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 Chemical compound COc1ccc(Cl)c(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 WYTQVDBYGFCFCU-CTYIDZIISA-N 0.000 claims 1
- MURHVXZELMNENA-RUCARUNLSA-N COc1ccc(cc1)-c1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound COc1ccc(cc1)-c1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 MURHVXZELMNENA-RUCARUNLSA-N 0.000 claims 1
- SCPATYFCJLYFTI-CTYIDZIISA-N COc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)c(C)c1Cl Chemical compound COc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)c(C)c1Cl SCPATYFCJLYFTI-CTYIDZIISA-N 0.000 claims 1
- LQOCDLGXBNNPRZ-MQMHXKEQSA-N COc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c(C)c1Cl Chemical compound COc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c(C)c1Cl LQOCDLGXBNNPRZ-MQMHXKEQSA-N 0.000 claims 1
- KEVHTHIFWWAZOE-RHDGDCLCSA-N Cc1[nH]nc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1-c1ccc(F)cc1 Chemical compound Cc1[nH]nc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1-c1ccc(F)cc1 KEVHTHIFWWAZOE-RHDGDCLCSA-N 0.000 claims 1
- NICNGJBCHOEQET-MQMHXKEQSA-N Cc1c(Cl)c(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)C(F)(F)F Chemical compound Cc1c(Cl)c(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)C(F)(F)F NICNGJBCHOEQET-MQMHXKEQSA-N 0.000 claims 1
- XDRNJBXWFMSCQY-KOMQPUFPSA-N Cc1c2COCCc2nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound Cc1c2COCCc2nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F XDRNJBXWFMSCQY-KOMQPUFPSA-N 0.000 claims 1
- BOEPJERVBHNDEP-IRJFHVNHSA-N Cc1cc(-c2ccccc2)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound Cc1cc(-c2ccccc2)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 BOEPJERVBHNDEP-IRJFHVNHSA-N 0.000 claims 1
- HSTHFIYASRGMSO-KOMQPUFPSA-N Cc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound Cc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 HSTHFIYASRGMSO-KOMQPUFPSA-N 0.000 claims 1
- JKLLQCCOTMYIGE-JCNLHEQBSA-N Cc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(cnc2C)C(F)(F)F)n1 Chemical compound Cc1cc(C)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(cnc2C)C(F)(F)F)n1 JKLLQCCOTMYIGE-JCNLHEQBSA-N 0.000 claims 1
- ACRFXQOGJGDSAR-KOMQPUFPSA-N Cc1cc(CO)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 Chemical compound Cc1cc(CO)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 ACRFXQOGJGDSAR-KOMQPUFPSA-N 0.000 claims 1
- TWBGPAWOFRHVHU-KOMQPUFPSA-N Cc1cc(CO)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C Chemical compound Cc1cc(CO)nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C TWBGPAWOFRHVHU-KOMQPUFPSA-N 0.000 claims 1
- RZZTZRLSAVCZQN-CTYIDZIISA-N Cc1cc(n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1)C(F)(F)F Chemical compound Cc1cc(n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1)C(F)(F)F RZZTZRLSAVCZQN-CTYIDZIISA-N 0.000 claims 1
- HDVKCZBTJPPTOY-CYWCHRQTSA-N Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)-c1ccc(F)cc1 Chemical compound Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)-c1ccc(F)cc1 HDVKCZBTJPPTOY-CYWCHRQTSA-N 0.000 claims 1
- UTRUIFXMYSIHGC-XGAFWQRZSA-N Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)-c1ccccc1 Chemical compound Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)-c1ccccc1 UTRUIFXMYSIHGC-XGAFWQRZSA-N 0.000 claims 1
- FAZYIPVDSLLNSX-IRJFHVNHSA-N Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)-c1cccnc1 Chemical compound Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)-c1cccnc1 FAZYIPVDSLLNSX-IRJFHVNHSA-N 0.000 claims 1
- KNLWVUPAERCOSC-CTYIDZIISA-N Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)C(F)(F)F Chemical compound Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C)C(F)(F)F KNLWVUPAERCOSC-CTYIDZIISA-N 0.000 claims 1
- PUNHDKOPTKUXQO-UKIBZPOASA-N Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F)-c1ccc(F)cc1 Chemical compound Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F)-c1ccc(F)cc1 PUNHDKOPTKUXQO-UKIBZPOASA-N 0.000 claims 1
- ZXYCVPWDDSAHKJ-RUCARUNLSA-N Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F)-c1ccc2OCOc2c1 Chemical compound Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F)-c1ccc2OCOc2c1 ZXYCVPWDDSAHKJ-RUCARUNLSA-N 0.000 claims 1
- NREOSOPDMOHIQZ-IRJFHVNHSA-N Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F)-c1ccccc1 Chemical compound Cc1cc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F)-c1ccccc1 NREOSOPDMOHIQZ-IRJFHVNHSA-N 0.000 claims 1
- SWJNIOVHGPGTRE-KOMQPUFPSA-N Cc1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 Chemical compound Cc1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)n1 SWJNIOVHGPGTRE-KOMQPUFPSA-N 0.000 claims 1
- BOGDYGMZJCHOJB-CTYIDZIISA-N Cc1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound Cc1ccn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 BOGDYGMZJCHOJB-CTYIDZIISA-N 0.000 claims 1
- OGIHZODTWUGGET-KOMQPUFPSA-N Cc1ccnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C Chemical compound Cc1ccnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(Cl)cnc1C OGIHZODTWUGGET-KOMQPUFPSA-N 0.000 claims 1
- GZVHOFYARYVQJJ-CTYIDZIISA-N Cc1ccnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound Cc1ccnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F GZVHOFYARYVQJJ-CTYIDZIISA-N 0.000 claims 1
- GOLGRQFUTILOBC-JCNLHEQBSA-N Cc1cn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)nc1C Chemical compound Cc1cn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)nc1C GOLGRQFUTILOBC-JCNLHEQBSA-N 0.000 claims 1
- CYEKERUNBYWVCC-KOMQPUFPSA-N Cc1cn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)nc1C Chemical compound Cc1cn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)nc1C CYEKERUNBYWVCC-KOMQPUFPSA-N 0.000 claims 1
- IWZLBYMKLCNUGG-JCNLHEQBSA-N Cc1cnn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)c1C Chemical compound Cc1cnn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)c1C IWZLBYMKLCNUGG-JCNLHEQBSA-N 0.000 claims 1
- SSMMCKPZYZKUOL-CTYIDZIISA-N Cc1cnn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1 Chemical compound Cc1cnn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1 SSMMCKPZYZKUOL-CTYIDZIISA-N 0.000 claims 1
- MCOFQVSKAQKXFA-KOMQPUFPSA-N Cc1cnn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1C Chemical compound Cc1cnn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1C MCOFQVSKAQKXFA-KOMQPUFPSA-N 0.000 claims 1
- XOEVJFUGRMCEEV-KOMQPUFPSA-N Cc1n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)nc2ncccc12 Chemical compound Cc1n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)nc2ncccc12 XOEVJFUGRMCEEV-KOMQPUFPSA-N 0.000 claims 1
- DGQFUXNDZNNZKO-RZDIXWSQSA-N Cc1n[nH]c(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1-c1cccnc1 Chemical compound Cc1n[nH]c(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1-c1cccnc1 DGQFUXNDZNNZKO-RZDIXWSQSA-N 0.000 claims 1
- JROCNAKNJYZGPD-AULYBMBSSA-N Cc1nc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F)C(F)(F)F Chemical compound Cc1nc(nn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F)C(F)(F)F JROCNAKNJYZGPD-AULYBMBSSA-N 0.000 claims 1
- ZSEVJFCMMJBALK-CTYIDZIISA-N Cc1ncc(Cl)cc1C(=O)N[C@H]1CC[C@H](CNc2n[nH]c3cccnc23)CC1 Chemical compound Cc1ncc(Cl)cc1C(=O)N[C@H]1CC[C@H](CNc2n[nH]c3cccnc23)CC1 ZSEVJFCMMJBALK-CTYIDZIISA-N 0.000 claims 1
- LTMGOEAKUDIGQE-RZDIXWSQSA-N Cc1ncc(Cl)cc1C(=O)N[C@H]1CC[C@H](Cn2cc3CCCCc3n2)CC1 Chemical compound Cc1ncc(Cl)cc1C(=O)N[C@H]1CC[C@H](Cn2cc3CCCCc3n2)CC1 LTMGOEAKUDIGQE-RZDIXWSQSA-N 0.000 claims 1
- FADYGSQMYYEHDY-SAZUREKKSA-N Cc1ncc(Cl)cc1C(=O)N[C@H]1CC[C@H](Cn2ccc3cnc(Cl)nc23)CC1 Chemical compound Cc1ncc(Cl)cc1C(=O)N[C@H]1CC[C@H](Cn2ccc3cnc(Cl)nc23)CC1 FADYGSQMYYEHDY-SAZUREKKSA-N 0.000 claims 1
- RFVDFEZUUMDSBQ-RZDIXWSQSA-N Cc1ncc(Cl)cc1C(=O)N[C@H]1CC[C@H](Cn2ncc3CCCCc23)CC1 Chemical compound Cc1ncc(Cl)cc1C(=O)N[C@H]1CC[C@H](Cn2ncc3CCCCc23)CC1 RFVDFEZUUMDSBQ-RZDIXWSQSA-N 0.000 claims 1
- INLXHTRQHXFAKP-MQMHXKEQSA-N Cc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)c(c1Cl)C(F)(F)F Chemical compound Cc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)c(c1Cl)C(F)(F)F INLXHTRQHXFAKP-MQMHXKEQSA-N 0.000 claims 1
- MVBNWIUDYOMZGB-KOMQPUFPSA-N Cc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c2CCOCc12 Chemical compound Cc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c2CCOCc12 MVBNWIUDYOMZGB-KOMQPUFPSA-N 0.000 claims 1
- YJPXJYNABJDGSJ-KOMQPUFPSA-N Cc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c2ncccc12 Chemical compound Cc1nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c2ncccc12 YJPXJYNABJDGSJ-KOMQPUFPSA-N 0.000 claims 1
- 102400000739 Corticotropin Human genes 0.000 claims 1
- 101800000414 Corticotropin Proteins 0.000 claims 1
- KAUBLHQZGOJOTO-SAZUREKKSA-N FC(F)(F)C1=CC=C(Cl)C(C(=O)N[C@@H]2CC[C@@H](CN3C=4CCCC=4C=N3)CC2)=C1 Chemical compound FC(F)(F)C1=CC=C(Cl)C(C(=O)N[C@@H]2CC[C@@H](CN3C=4CCCC=4C=N3)CC2)=C1 KAUBLHQZGOJOTO-SAZUREKKSA-N 0.000 claims 1
- NVMLZAHNDZRDTM-SAZUREKKSA-N FC(F)(F)C1=CC=C(Cl)C(C(=O)N[C@@H]2CC[C@@H](CN3N=C4CCCC4=C3)CC2)=C1 Chemical compound FC(F)(F)C1=CC=C(Cl)C(C(=O)N[C@@H]2CC[C@@H](CN3N=C4CCCC4=C3)CC2)=C1 NVMLZAHNDZRDTM-SAZUREKKSA-N 0.000 claims 1
- NYNKIADZYKNXRB-CZIWCDLHSA-N FC(F)(F)C1=CC=C(Cl)C(C(=O)N[C@@H]2CC[C@@H](CNC3=C(C=NN3)C=3C=NC=CC=3)CC2)=C1 Chemical compound FC(F)(F)C1=CC=C(Cl)C(C(=O)N[C@@H]2CC[C@@H](CNC3=C(C=NN3)C=3C=NC=CC=3)CC2)=C1 NYNKIADZYKNXRB-CZIWCDLHSA-N 0.000 claims 1
- JTXWCOJCULSGOS-KOMQPUFPSA-N FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](CNc2cnc3ccccn23)CC1 Chemical compound FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](CNc2cnc3ccccn23)CC1 JTXWCOJCULSGOS-KOMQPUFPSA-N 0.000 claims 1
- QIABATXBJSRVNW-CZIWCDLHSA-N FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2cc3CCCCc3n2)CC1 Chemical compound FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2cc3CCCCc3n2)CC1 QIABATXBJSRVNW-CZIWCDLHSA-N 0.000 claims 1
- QVFPEYRRSCTBDF-SAZUREKKSA-N FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2cc3cccnc3n2)CC1 Chemical compound FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2cc3cccnc3n2)CC1 QVFPEYRRSCTBDF-SAZUREKKSA-N 0.000 claims 1
- RFXURXZCABSTOU-RZDIXWSQSA-N FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2ccc(n2)-c2ccncc2)CC1 Chemical compound FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2ccc(n2)-c2ccncc2)CC1 RFXURXZCABSTOU-RZDIXWSQSA-N 0.000 claims 1
- FXELBJLAISKIEP-NNUKFRKNSA-N FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2ccc3cnc(Cl)nc23)CC1 Chemical compound FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2ccc3cnc(Cl)nc23)CC1 FXELBJLAISKIEP-NNUKFRKNSA-N 0.000 claims 1
- HFWXJGZENVQNEX-MQMHXKEQSA-N FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2cccn2)CC1 Chemical compound FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2cccn2)CC1 HFWXJGZENVQNEX-MQMHXKEQSA-N 0.000 claims 1
- FDDYZVHFNPZEPU-MQMHXKEQSA-N FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2cnc3cncnc23)CC1 Chemical compound FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2cnc3cncnc23)CC1 FDDYZVHFNPZEPU-MQMHXKEQSA-N 0.000 claims 1
- UHNGJBNIXCIYSE-CZIWCDLHSA-N FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2ncc3CCCCc23)CC1 Chemical compound FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2ncc3CCCCc23)CC1 UHNGJBNIXCIYSE-CZIWCDLHSA-N 0.000 claims 1
- GGOWOZHBHDZNNV-SAZUREKKSA-N FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2ncc3cccnc23)CC1 Chemical compound FC(F)(F)c1ccc(Cl)c(c1)C(=O)N[C@H]1CC[C@H](Cn2ncc3cccnc23)CC1 GGOWOZHBHDZNNV-SAZUREKKSA-N 0.000 claims 1
- DVAOSYWVHRGCFB-KOMQPUFPSA-N N([C@H]1CC[C@@H](CC1)CN1N=C(C=2CCCC=21)C)C(=O)C1=CC(C(F)(F)F)=CC=C1Cl Chemical compound N([C@H]1CC[C@@H](CC1)CN1N=C(C=2CCCC=21)C)C(=O)C1=CC(C(F)(F)F)=CC=C1Cl DVAOSYWVHRGCFB-KOMQPUFPSA-N 0.000 claims 1
- GZJZJHZZIXBJPN-JCNLHEQBSA-N N([C@H]1CC[C@@H](CC1)CN1N=C(C=2CCCC=21)C)C(=O)C1=CC(Cl)=CN=C1C Chemical compound N([C@H]1CC[C@@H](CC1)CN1N=C(C=2CCCC=21)C)C(=O)C1=CC(Cl)=CN=C1C GZJZJHZZIXBJPN-JCNLHEQBSA-N 0.000 claims 1
- UITYSKSTPYSBFO-KOMQPUFPSA-N N([C@H]1CC[C@@H](CC1)CN1N=C2CCCC2=C1C)C(=O)C1=CC(C(F)(F)F)=CC=C1Cl Chemical compound N([C@H]1CC[C@@H](CC1)CN1N=C2CCCC2=C1C)C(=O)C1=CC(C(F)(F)F)=CC=C1Cl UITYSKSTPYSBFO-KOMQPUFPSA-N 0.000 claims 1
- MZFJTGCQAXWAHK-JCNLHEQBSA-N N([C@H]1CC[C@@H](CC1)CN1N=C2CCCC2=C1C)C(=O)C1=CC(Cl)=CN=C1C Chemical compound N([C@H]1CC[C@@H](CC1)CN1N=C2CCCC2=C1C)C(=O)C1=CC(Cl)=CN=C1C MZFJTGCQAXWAHK-JCNLHEQBSA-N 0.000 claims 1
- CDUUPHUMLLMQEX-RZDIXWSQSA-N OC(=O)Cc1ccc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1 Chemical compound OC(=O)Cc1ccc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1 CDUUPHUMLLMQEX-RZDIXWSQSA-N 0.000 claims 1
- URXQQAXKBPTAJS-CZIWCDLHSA-N OC(=O)Cc1cccc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1 Chemical compound OC(=O)Cc1cccc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)c1 URXQQAXKBPTAJS-CZIWCDLHSA-N 0.000 claims 1
- CHGQSWSEIJDPNB-WJYNOGRTSA-N OC(=O)c1ccc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1 Chemical compound OC(=O)c1ccc(NC[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)cc1 CHGQSWSEIJDPNB-WJYNOGRTSA-N 0.000 claims 1
- PLRDZHSHIHZEKO-AULYBMBSSA-N OCc1c(Cl)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F Chemical compound OCc1c(Cl)cnn1C[C@H]1CC[C@@H](CC1)NC(=O)c1cc(ccc1Cl)C(F)(F)F PLRDZHSHIHZEKO-AULYBMBSSA-N 0.000 claims 1
- ASTWAFFZNDYSLW-MQMHXKEQSA-N OCc1cc(CO)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 Chemical compound OCc1cc(CO)n(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(ccc2Cl)C(F)(F)F)n1 ASTWAFFZNDYSLW-MQMHXKEQSA-N 0.000 claims 1
- FZPRQRQELHONGW-HZBAIFDJSA-N [2H]c1c(C)nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)c1C Chemical compound [2H]c1c(C)nn(C[C@H]2CC[C@@H](CC2)NC(=O)c2cc(Cl)cnc2C)c1C FZPRQRQELHONGW-HZBAIFDJSA-N 0.000 claims 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 1
- 229960000258 corticotropin Drugs 0.000 claims 1
- 230000002074 deregulated effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003488 releasing hormone Substances 0.000 claims 1
- 0 Cc1c(*)c(*)n[n]1C[C@](CC1)CC[C@@]1NC(*)=O Chemical compound Cc1c(*)c(*)n[n]1C[C@](CC1)CC[C@@]1NC(*)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30057610P | 2010-02-02 | 2010-02-02 | |
| US61/300,576 | 2010-02-02 | ||
| US201061424258P | 2010-12-17 | 2010-12-17 | |
| US61/424,258 | 2010-12-17 | ||
| PCT/EP2011/051293 WO2011095450A1 (en) | 2010-02-02 | 2011-01-31 | Cyclohexyl amide derivatives as crf receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518845A JP2013518845A (ja) | 2013-05-23 |
| JP2013518845A5 true JP2013518845A5 (enExample) | 2014-03-13 |
| JP5748777B2 JP5748777B2 (ja) | 2015-07-15 |
Family
ID=44354989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551586A Expired - Fee Related JP5748777B2 (ja) | 2010-02-02 | 2011-01-31 | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8835444B2 (enExample) |
| EP (1) | EP2531490B1 (enExample) |
| JP (1) | JP5748777B2 (enExample) |
| CN (1) | CN102753527B (enExample) |
| ES (1) | ES2527849T3 (enExample) |
| WO (1) | WO2011095450A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| IL304134B2 (en) | 2014-01-21 | 2025-04-01 | Neurocrine Biosciences Inc | Preparations for the treatment of congenital adrenal hyperplasia |
| CN107530333B (zh) | 2015-02-27 | 2022-03-15 | 钙医学公司 | 胰腺炎治疗 |
| JP6738575B2 (ja) | 2015-08-07 | 2020-08-12 | カルシメディカ，インク． | 脳卒中および外傷性脳損傷の処置のためのｃｒａｃチャネル阻害剤の使用 |
| JOP20170153A1 (ar) | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| CA3066711A1 (en) | 2017-07-31 | 2019-02-07 | Novartis Ag | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
| AU2018375308A1 (en) | 2017-11-29 | 2020-06-25 | The Rockefeller University | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases |
| RU2020122711A (ru) | 2017-12-13 | 2022-01-17 | ПРАКСИС БАЙОТЕК ЭлЭлСи | Ингибиторы пути интегрированной реакции на стресс |
| BR112020020708A8 (pt) * | 2018-04-09 | 2022-10-18 | Raqualia Pharma Inc | Derivados da ureia cíclica fundidã como antagonista crhr2 |
| SG11202011014VA (en) | 2018-06-05 | 2020-12-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| FI3984523T3 (fi) | 2018-12-07 | 2025-10-21 | Neurocrine Biosciences Inc | Crf1-reseptorin antagonisti, lääkeformulaatioita ja niiden kiinteitä muotoja synnynnäisen lisämunuaisten liikakasvun hoitoon |
| CA3142748A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| CN114206829A (zh) * | 2019-06-12 | 2022-03-18 | 普拉西斯生物技术有限责任公司 | 整合应激反应通路抑制剂 |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| TW202140480A (zh) * | 2020-01-15 | 2021-11-01 | 日商拉夸里亞創藥股份有限公司 | 作為crhr2拮抗劑之螺雜環衍生物 |
| TW202229254A (zh) | 2020-09-30 | 2022-08-01 | 日商拉夸里亞創藥股份有限公司 | 作為crhr2拮抗劑之3-羥基吲哚酮衍生物 |
| KR20240012344A (ko) | 2020-11-13 | 2024-01-29 | 칼시메디카, 인크 | Crac 채널 억제제의 개선된 합성 |
Family Cites Families (198)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| GB9802251D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
| BR9914215A (pt) | 1998-10-02 | 2001-07-03 | Novartis Ag | Antagonistas de mglur5 para o tratamento da dor e da ansiedade |
| US6525203B1 (en) | 1999-03-12 | 2003-02-25 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
| RU2003130221A (ru) | 2001-03-26 | 2005-04-10 | Новартис АГ (CH) | Сконденсированные пиридиновые производные, предназначенные для применения в качестве антагонистов ваниллоидного рецептора при лечении боли |
| JP4206272B2 (ja) | 2001-03-29 | 2009-01-07 | サイナージィ ファーマスーティカルズ、インコーポレイテッド | 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト |
| JP3894035B2 (ja) | 2001-07-04 | 2007-03-14 | 東レ株式会社 | 炭素繊維強化基材、それからなるプリフォームおよび複合材料 |
| TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
| US6696468B2 (en) | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
| SE0201940D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New combination II |
| DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
| AR042206A1 (es) | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| GB0302876D0 (en) | 2003-02-07 | 2003-03-12 | Novartis Ag | Organic compounds |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| JP2004277319A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物 |
| JP2004277318A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物 |
| ES2391974T3 (es) | 2003-06-13 | 2012-12-03 | Ironwood Pharmaceuticals, Inc. | Procedimientos y composiciones para el tratamiento de trastornos gastrointestinales |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| US7491695B2 (en) | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| EP1505064A1 (en) | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
| EP1656145A1 (en) | 2003-08-12 | 2006-05-17 | F. Hoffmann-La Roche Ag | Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
| ATE374190T1 (de) | 2003-08-12 | 2007-10-15 | Hoffmann La Roche | Tetrahydrochinazolinderivate als cfr-antagonisten |
| EP1664010A1 (en) | 2003-08-29 | 2006-06-07 | Vernalis (R&D) Limited | Sulfonamides antagonising n-type calcium channels |
| CA2537916A1 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| RS20060145A (sr) | 2003-09-03 | 2008-06-05 | Pfizer Inc., | Jedinjenja benzoimidazolona sa 5-ht4 receptor antagonističkim dejstvom |
| JP2005082508A (ja) | 2003-09-05 | 2005-03-31 | Dainippon Pharmaceut Co Ltd | ２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物 |
| CN1878773A (zh) | 2003-09-05 | 2006-12-13 | 神经能质公司 | 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶 |
| RU2006111469A (ru) | 2003-09-09 | 2007-10-27 | Оно Фармасьютикал Ко., Лтд. (Jp) | Антагонисты crf и гетеробициклические соединения |
| GB0322612D0 (en) | 2003-09-26 | 2003-10-29 | Novartis Ag | Organic compounds |
| JP2005104896A (ja) | 2003-09-30 | 2005-04-21 | Dainippon Pharmaceut Co Ltd | ２−アルコキシ−６−アミノ−５−ハロゲノピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物 |
| JP2007507514A (ja) | 2003-09-30 | 2007-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キノキサリン化合物 |
| NZ546259A (en) | 2003-09-30 | 2009-05-31 | Janssen Pharmaceutica Nv | Benzoimidazole compounds |
| CN1870999A (zh) | 2003-10-31 | 2006-11-29 | 阿斯利康(瑞典)有限公司 | 炔烃ⅰ |
| US7714009B2 (en) | 2003-10-31 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| WO2005047270A2 (en) | 2003-11-10 | 2005-05-26 | Merck & Co., Inc. | Substituted triazoles as sodium channel blockers |
| US7208596B2 (en) | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
| WO2005054239A1 (en) | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| US7211568B2 (en) | 2003-12-18 | 2007-05-01 | Kosan Biosciences Incorporated | 9-Desoxoerythromycin compounds as prokinetic agents |
| MXPA06006674A (es) | 2003-12-19 | 2007-04-16 | Astrazeneca Ab | 5-fluoro-, cloro- y ciano-piridin-2-il-tetrazoles como ligandos del receptor-5 de glutamato metabotropico. |
| MY143499A (en) * | 2003-12-22 | 2011-05-31 | Sb Pharmco Inc | Crf receptor antagonist and methods relating thereto |
| JP2005206590A (ja) | 2003-12-25 | 2005-08-04 | Mitsubishi Pharma Corp | ナトリウムチャネルサイト２選択的阻害剤 |
| US7176218B2 (en) | 2004-01-07 | 2007-02-13 | Aryx Therapeutics | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| TW200530181A (en) | 2004-01-13 | 2005-09-16 | Bristol Myers Squibb Co | Heterocyclic compounds useful as growth hormone secretagogues |
| US7691881B2 (en) | 2004-01-29 | 2010-04-06 | Pfizer Inc | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| MXPA06009023A (es) | 2004-02-18 | 2007-03-08 | Astrazeneca Ab | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico. |
| KR20070027503A (ko) | 2004-02-18 | 2007-03-09 | 아스트라제네카 아베 | 트리아졸 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도 |
| CN1934097A (zh) | 2004-02-18 | 2007-03-21 | 阿斯利康(瑞典)有限公司 | 炔基化哌嗪化合物及其作为代谢型谷氨酸受体拮抗剂的应用 |
| CN1934112A (zh) | 2004-02-18 | 2007-03-21 | 阿斯利康(瑞典)有限公司 | 稠合的杂环化合物及其作为代谢型谷氨酸受体拮抗剂的应用 |
| TW200533348A (en) | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| EP1716125B1 (en) | 2004-02-18 | 2013-06-19 | AstraZeneca AB | Tetrazole compounds and their use as metabotropic glutamate receptor antagonits |
| TW200538108A (en) | 2004-02-19 | 2005-12-01 | Astrazeneca Ab | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| TW200538180A (en) | 2004-02-20 | 2005-12-01 | Astrazeneca Ab | New compounds |
| WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| US7087749B2 (en) | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| CA2560896C (en) | 2004-03-25 | 2013-06-18 | Janssen Pharmaceutica, N.V. | Imidazole compounds |
| US20080280873A1 (en) | 2004-03-29 | 2008-11-13 | Jun Liang | Biaryl Substituted Pyrazinones as Sodium Channel Blockers |
| US20050261332A1 (en) | 2004-04-02 | 2005-11-24 | Distefano Peter | Sulfonamides and uses thereof |
| TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US20080015196A1 (en) | 2004-04-16 | 2008-01-17 | Neurogen Corporation | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands |
| GB0412768D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| PE20060526A1 (es) | 2004-06-15 | 2006-07-13 | Schering Corp | Compuestos triciclicos como antagonistas de mglur1 |
| MXPA06014486A (es) | 2004-06-15 | 2007-03-01 | Pfizer | Derivados de acido carboxilico de bencimidazolona. |
| SE0401653D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
| US20060035939A1 (en) | 2004-07-14 | 2006-02-16 | Japan Tobacco Inc. | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity |
| AU2005260821B2 (en) | 2004-07-15 | 2010-02-18 | Japan Tobacco Inc. | Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor |
| US20080039430A1 (en) | 2004-07-19 | 2008-02-14 | Ali Ouaissi | Pharmaceutical Compositions For The Treatment Of Leishmaniasis |
| JP2008508221A (ja) | 2004-07-28 | 2008-03-21 | グラクソ グループ リミテッド | 消化器疾患の治療に有用なピペラジン誘導体 |
| ITMI20041566A1 (it) | 2004-07-30 | 2004-10-30 | Indena Spa | "trpv1 agonisti, formulazioni che li contengono e loro usi" |
| WO2006016218A1 (en) | 2004-08-03 | 2006-02-16 | Pfizer Japan Inc. | Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists |
| WO2006023757A2 (en) | 2004-08-19 | 2006-03-02 | University Of Virginia Patent Foundation | Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents |
| EP1789413A1 (en) | 2004-09-13 | 2007-05-30 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| GB0420424D0 (en) | 2004-09-14 | 2004-10-20 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
| US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| SE0402284D0 (sv) | 2004-09-21 | 2004-09-21 | Astrazeneca Ab | New heterocyclic amides |
| EP1797090A4 (en) | 2004-09-27 | 2009-11-11 | Elixir Pharmaceuticals Inc | SULFONAMIDES AND USES THEREOF |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| EP2380889B1 (en) | 2004-10-07 | 2013-06-26 | Merck Sharp & Dohme Corp. | Thiazolyl MGLUR5 antagonists and methods for their use |
| EP1799661A1 (en) | 2004-10-08 | 2007-06-27 | AstraZeneca AB | New hydroxymethylbenzothiazoles amides |
| US8143425B2 (en) | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| WO2006044527A1 (en) | 2004-10-15 | 2006-04-27 | Amgen Inc. | Imidazole derivatives as vanilloid receptor ligands |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| ES2326827T3 (es) | 2004-10-19 | 2009-10-20 | Smithkline Beecham (Cork) Limited | Anatagonistas del receptor de crf y metodos relacionados. |
| EP1807418A2 (en) | 2004-10-22 | 2007-07-18 | Amgen, Inc | Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament |
| WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| JP5086091B2 (ja) | 2004-11-05 | 2012-11-28 | セラヴァンス， インコーポレーテッド | ５−ｈｔ４受容体アゴニスト化合物 |
| ES2327142T3 (es) | 2004-11-05 | 2009-10-26 | Theravance, Inc. | Compuestos de quinolinona-carboxamida. |
| AU2005303893A1 (en) | 2004-11-11 | 2006-05-18 | Argenta Discovery Ltd | Pyrimidine compounds as histamine modulators |
| US20060111416A1 (en) | 2004-11-24 | 2006-05-25 | Lane Charlotte A L | Octahydropyrrolo[3,4-C]pyrrole derivatives |
| KR101250824B1 (ko) | 2004-11-24 | 2013-04-05 | 아보트 러보러터리즈 | 바닐로이드 수용체 아형 1(ｖｒ1) 수용체를 억제하는크로마닐우레아 화합물 및 이의 용도 |
| WO2006058338A2 (en) | 2004-11-29 | 2006-06-01 | Janssen Pharmaceutica N.V. | 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor |
| US7875627B2 (en) | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
| US20060128710A1 (en) | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| US7615570B2 (en) | 2004-12-13 | 2009-11-10 | Abbott Laboratories | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| SE0403118D0 (sv) | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | New compounds 2 |
| SE0403117D0 (sv) | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | New compounds 1 |
| RU2404179C2 (ru) | 2004-12-22 | 2010-11-20 | Тереванс, Инк. | Индазол-карбоксамидные соединения |
| SE0403171D0 (sv) | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | New compounds |
| EP1836203A2 (en) | 2005-01-14 | 2007-09-26 | Neurogen Corporation | Heteroaryl substituted quinolin-4-ylamine analogues |
| ATE474839T1 (de) | 2005-01-14 | 2010-08-15 | Hoffmann La Roche | Thiazol-4-carboxamid-derivate als mglur5- antagonisten |
| WO2006078907A1 (en) | 2005-01-20 | 2006-07-27 | Amgen Inc. | 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments |
| US7301022B2 (en) | 2005-02-15 | 2007-11-27 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US20060183901A1 (en) | 2005-02-17 | 2006-08-17 | Theravance, Inc. | Crystalline form of an indazole-carboxamide compound |
| GB0503646D0 (en) | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
| DE602006014531D1 (de) | 2005-03-03 | 2010-07-08 | Janssen Pharmaceutica Nv | Substituierte oxadiazaspiro-ä5.5ü-undecanonderivate und ihre verwendung als neurokininantagonisten |
| JP4906839B2 (ja) | 2005-03-10 | 2012-03-28 | ファイザー株式会社 | 置換ｎ−スルホニルアミノフェニルエチル−２−フェノキシアセトアミド化合物 |
| US20060211710A1 (en) | 2005-03-17 | 2006-09-21 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| EP1863756A1 (en) | 2005-03-24 | 2007-12-12 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
| GB0506147D0 (en) | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006105117A2 (en) | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| TWI377206B (en) | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| WO2006113769A1 (en) | 2005-04-15 | 2006-10-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| GB0508318D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| WO2006116563A1 (en) | 2005-04-25 | 2006-11-02 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| GB0508314D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| ATE526320T1 (de) | 2005-05-11 | 2011-10-15 | Abbott Lab | Antagonisten des vanilloidrezeptors vom subtyp 1 (vr1), und anwendungen davon |
| GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| CA2607929A1 (en) | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1) |
| AU2006247487A1 (en) | 2005-05-12 | 2006-11-23 | Amgen Inc. | Antipyretic agents against VR1-antagonist-induced increases in body temperature |
| DE102005023588A1 (de) | 2005-05-18 | 2006-11-23 | Grünenthal GmbH | Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln |
| GB0510141D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| AU2006248655A1 (en) | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Substituted Oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510140D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| DE102005044813A1 (de) | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DE102005044814A1 (de) | 2005-05-19 | 2006-11-23 | Grünenthal GmbH | Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DE102005023784A1 (de) | 2005-05-19 | 2006-11-30 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DE102005024012A1 (de) | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln |
| US7582611B2 (en) | 2005-05-24 | 2009-09-01 | Pfizer Inc. | Motilide compounds |
| MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
| ATE495171T1 (de) | 2005-06-07 | 2011-01-15 | Theravance Inc | Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors |
| MX2007015617A (es) | 2005-06-10 | 2008-03-06 | Elixir Pharmaceuticals Inc | Compuestos de sulfonamida y usos de los mismos. |
| AU2006259891A1 (en) | 2005-06-23 | 2006-12-28 | Albireo Ab | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases |
| JP2008546768A (ja) | 2005-06-23 | 2008-12-25 | アストラゼネカ・アクチエボラーグ | 胃腸疾患を治療するためのニューロキニン受容体アンタゴニストとしての新規なアゼチジン誘導体 |
| WO2007004041A2 (en) | 2005-07-05 | 2007-01-11 | Orchid Research Laboratories Limited | New compounds and their pharmaceutical use |
| WO2007005951A2 (en) | 2005-07-05 | 2007-01-11 | Aryx Therapeutics, Inc. | Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| EP1902022A1 (en) | 2005-07-12 | 2008-03-26 | Glaxo Group Limited | Piperazine heteroaryl derivates as gpr38 agonists |
| WO2007010390A1 (en) | 2005-07-22 | 2007-01-25 | Pfizer Japan Inc. | Indazolecarboxamide derivatives as 5ht4 receptor agonists |
| JP4879265B2 (ja) | 2005-07-22 | 2012-02-22 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | 成長ホルモン分泌促進薬 |
| KR101281435B1 (ko) | 2005-07-26 | 2013-07-02 | 글락소 그룹 리미티드 | 벤질피페라진 유도체 및 그의 의학적 용도 |
| EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| EP1940441A4 (en) | 2005-08-19 | 2010-01-27 | Ironwood Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS |
| WO2007023242A1 (en) | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
| EP1943247A1 (en) | 2005-08-25 | 2008-07-16 | Merz Pharma GmbH & Co.KGaA | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
| EP1940785A2 (en) | 2005-09-08 | 2008-07-09 | SmithKline Beecham Corporation | Acyclic 1,4-diamines and uses thereof |
| WO2007031529A1 (en) | 2005-09-13 | 2007-03-22 | Palau Pharma, S.A. | 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity |
| AR056087A1 (es) | 2005-09-29 | 2007-09-19 | Astrazeneca Ab | Derivados de azetidina como antagonistas de receptores de neuroquina nk |
| AR057828A1 (es) | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
| AR058807A1 (es) | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
| HUP0500921A2 (en) | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Tetrazole derivatives, process for their preparation and their use |
| HUP0500920A2 (en) | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Oxadiazole derivatives, process for their preparation and their use |
| AP2008004432A0 (en) | 2005-10-07 | 2008-04-30 | Glenmark Pharmaceuticals Sa | Substituted benzofused derivatives and their use as vanilloid receptor ligands |
| US20070088073A1 (en) | 2005-10-19 | 2007-04-19 | Allergan, Inc. | Method for treating pain |
| NZ593684A (en) | 2005-10-19 | 2012-11-30 | Gruenenthal Chemie | Novel vanilloid receptor ligands and their use for producing medicaments |
| US7902251B2 (en) | 2005-10-19 | 2011-03-08 | Allergan, Inc. | Method for treating pain |
| US7538110B2 (en) | 2005-10-27 | 2009-05-26 | Adolor Corporation | Opioid antagonists |
| JP2009513659A (ja) | 2005-10-28 | 2009-04-02 | アボット・ラボラトリーズ | Ｔｒｐｖ１受容体を阻害するインダゾール誘導体 |
| TW200732327A (en) | 2005-10-28 | 2007-09-01 | Glaxo Group Ltd | Novel compound |
| JP2007122605A (ja) | 2005-10-31 | 2007-05-17 | Fujitsu Ltd | インピーダンス回路、電源装置 |
| US20070105920A1 (en) | 2005-11-08 | 2007-05-10 | Akzo Nobel N.V. | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives |
| GB0525661D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
| NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| EP1829879A1 (en) | 2006-02-10 | 2007-09-05 | Cellzome (UK) Ltd. | Amino pyrimidine compounds for the treatment of inflammatory disorders |
| WO2007090854A1 (en) | 2006-02-10 | 2007-08-16 | Cellzome (Uk) Ltd. | Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders |
| WO2007090853A1 (en) | 2006-02-10 | 2007-08-16 | Cellzome (Uk) Ltd. | Enantiomers of amino pyrimidine compounds for the treatment of inflammatory disorders |
| GB0603550D0 (en) | 2006-02-22 | 2006-04-05 | Glaxo Group Ltd | Novel compounds |
| WO2007101158A2 (en) | 2006-02-24 | 2007-09-07 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2652677A1 (en) | 2006-02-24 | 2007-09-07 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US8597562B2 (en) | 2006-03-30 | 2013-12-03 | GM Global Technology Operations LLC | Composite products and methods of making the same |
| CN101460168B (zh) | 2006-03-31 | 2013-07-17 | 詹森药业有限公司 | 作为组胺h4受体调节剂的苯并咪唑-2-基吡啶 |
| US7507737B2 (en) | 2006-03-31 | 2009-03-24 | Janssen Pharmaceutica, N.V. | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor |
| TW200808709A (en) | 2006-03-31 | 2008-02-16 | Glaxo Group Ltd | Novel compounds |
| WO2007117401A2 (en) | 2006-04-07 | 2007-10-18 | Janssen Pharmaceutica N.V. | Indoles and benzoimidazoles as modulators of the histamine h4 receptor |
| JP2010523466A (ja) | 2006-04-13 | 2010-07-15 | グラクソ グループ リミテッド | 成長ホルモン分泌促進因子受容体アゴニストとしてのアリールおよびヘテロアリールスルホンアミド類 |
| TWI391386B (zh) | 2006-06-28 | 2013-04-01 | Glaxo Group Ltd | 化合物 |
| US8088733B2 (en) | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| CL2007003874A1 (es) * | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| BRPI0807046A2 (pt) | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
| US7947710B2 (en) | 2007-08-27 | 2011-05-24 | Theravance, Inc. | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| ES2465621T3 (es) | 2007-08-27 | 2014-06-06 | Theravance, Inc. | Compuestos de heteroarilalquil-8-azabiciclo[3.2.1]octano, como antagonistas de los receptores opiodes mu |
| WO2009029252A1 (en) | 2007-08-27 | 2009-03-05 | Theravance, Inc. | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| TWI423801B (zh) | 2007-08-27 | 2014-01-21 | Theravance Inc | 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物 |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US20110039860A1 (en) * | 2008-05-07 | 2011-02-17 | Cangming Yang | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| US20090298834A1 (en) * | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| EP2307377A1 (en) * | 2008-06-18 | 2011-04-13 | Pfizer Limited | Nicotinamide derivatives |
| US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
-
2011
- 2011-01-31 JP JP2012551586A patent/JP5748777B2/ja not_active Expired - Fee Related
- 2011-01-31 CN CN201180007786.4A patent/CN102753527B/zh not_active Expired - Fee Related
- 2011-01-31 ES ES11701824.2T patent/ES2527849T3/es active Active
- 2011-01-31 WO PCT/EP2011/051293 patent/WO2011095450A1/en not_active Ceased
- 2011-01-31 US US13/576,040 patent/US8835444B2/en not_active Expired - Fee Related
- 2011-01-31 EP EP11701824.2A patent/EP2531490B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518845A5 (enExample) | ||
| JP4290984B2 (ja) | Ｍｃｐ−１機能のアンタゴニストおよびその使用方法 | |
| TWI409062B (zh) | 作為５-ｈｔ２ａ５-羥色胺受體之調節子而有用於與該受體有關的疾病之治療之３-苯基吡唑衍生物 | |
| EP2300458B1 (de) | Substituierte 1-(diazinyl) pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren | |
| NZ778831A (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | |
| CN102869355B (zh) | Pde10抑制剂以及相关组合物和方法 | |
| HRP20181014T1 (hr) | Pirazoli derivati modulatori kalcijevih kanala aktiviranih oslobađanjem kalcija i metode za liječenje nesitnostaničnog karcinoma pluća | |
| JP2009519340A5 (enExample) | ||
| JP2015526442A5 (enExample) | ||
| JP2017512191A5 (enExample) | ||
| CN102666535B (zh) | 作为醛固酮合酶抑制剂的咪唑衍生物 | |
| RU2015142383A (ru) | Новейшие антагонисты trpa1-рецепторов | |
| CA2624879A1 (en) | Imidazopyridine derivatives as a2b adenosine receptor antagonists | |
| CN107074831B (zh) | Mapk抑制剂 | |
| RU2013134651A (ru) | Способ региоселективного синтеза производных 1-алкил-3-галогеналкилпиразол-4-карбоновой кислоты | |
| JP2017514839A5 (enExample) | ||
| JP2006514925A5 (enExample) | ||
| RU2009109354A (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| HRP20161177T1 (hr) | Modulator glukagonskog receptora | |
| RU2013112122A (ru) | Новые замещенные хинолиновые соединения как ингибиторы s-нитрозоглутатион-редуктазы | |
| JP2017512794A5 (enExample) | ||
| JP2013521286A5 (enExample) | ||
| CA2662766A1 (en) | Diaryl ether derivatives and uses thereof | |
| HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
| JPWO2004087641A1 (ja) | ヒドラゾン誘導体 |